Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study - PubMed (original) (raw)
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study
J Levy et al. Diabet Med. 1998 Apr.
Abstract
Secondary failure of plasma glucose control following initial successful response to diet therapy may be due to dietary indiscretion, or to progression of the intrinsic diabetic condition. We report a 10-year prospective natural history study of 432 newly diagnosed diabetic patients aged 40-69 years undertaken to assess the effect of intensive dietary management, where patients were transferred to insulin, or oral hypoglycaemic therapy (tolbutamide, metformin) by predetermined criteria of weight and plasma glucose. Secondary failure to diet therapy occurred in 41 patients in years 2-4, 67 patients in years 5-7, and 51 patients in years 8-10; 173 patients remained on diet alone until death or the end of the study. Continuation on diet alone was associated with a lower ongoing fasting plasma glucose, greater beta-cell function assessed by an oral glucose tolerance test at 6 months, and increasing age. The rate of rise of fasting plasma glucose was inversely related to the duration of successful dietary therapy, but mean weight remained constant in all groups while on diet alone. The ongoing fall in beta-cell function assessed by HOMA modelling closely mirrored the progressive rise in fasting plasma glucose: there was no change in mean insulin sensitivity in any of the groups.
Similar articles
- Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Brazg R, et al. Diabetes Obes Metab. 2007 Mar;9(2):186-93. doi: 10.1111/j.1463-1326.2006.00691.x. Diabetes Obes Metab. 2007. PMID: 17300594 Clinical Trial. - Macrovascular disease and hyperglycaemia: 10-year survival analysis in Type 2 diabetes mellitus: the Belfast Diet Study.
Hadden DR, Patterson CC, Atkinson AB, Kennedy L, Bell PM, McCance DR, Weaver JA. Hadden DR, et al. Diabet Med. 1997 Aug;14(8):663-72. doi: 10.1002/(SICI)1096-9136(199708)14:8<663::AID-DIA450>3.0.CO;2-Y. Diabet Med. 1997. PMID: 9272593 - Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF. Derosa G, et al. Metabolism. 2009 Aug;58(8):1059-66. doi: 10.1016/j.metabol.2009.03.007. Epub 2009 Jun 18. Metabolism. 2009. PMID: 19394976 Clinical Trial.
Cited by
- Dietary Fibre for the Prevention of Post-Pancreatitis Diabetes Mellitus: A Review of the Literature and Future Research Directions.
Li X, Petrov MS. Li X, et al. Nutrients. 2024 Feb 1;16(3):435. doi: 10.3390/nu16030435. Nutrients. 2024. PMID: 38337719 Free PMC article. Review. - Type 2 diabetes progression in an adult Ugandan population with new-onset diabetes: an observational prospective study.
Kibirige D, Sekitoleko I, Lumu W, Nyirenda MJ. Kibirige D, et al. BMC Prim Care. 2023 Oct 19;24(1):214. doi: 10.1186/s12875-023-02169-4. BMC Prim Care. 2023. PMID: 37858088 Free PMC article. - Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial.
Lian XF, Lu DH, Liu HL, Liu YJ, Yang Y, Lin Y, Xie F, Huang CH, Wu HM, Long AM, Hui CJ, Shi Y, Chen Y, Gao YF, Zhang F. Lian XF, et al. World J Clin Cases. 2023 Jul 26;11(21):5083-5096. doi: 10.12998/wjcc.v11.i21.5083. World J Clin Cases. 2023. PMID: 37583846 Free PMC article. Clinical Trial. - Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study.
Jianfang F, Wanxia X, Xiling G, Jing X, Wenjuan Y, Jianrong L, Qingzhen H, Kaiyan M, Jingxuan L, Taixiong C, Qian X, Mengying L, Jie M, Qiuhe J. Jianfang F, et al. J Diabetes Res. 2023 Jun 1;2023:2044090. doi: 10.1155/2023/2044090. eCollection 2023. J Diabetes Res. 2023. PMID: 37305429 Free PMC article. Clinical Trial. - Effectiveness and safety of human umbilical cord-mesenchymal stem cells for treating type 2 diabetes mellitus.
Lian XF, Lu DH, Liu HL, Liu YJ, Han XQ, Yang Y, Lin Y, Zeng QX, Huang ZJ, Xie F, Huang CH, Wu HM, Long AM, Deng LP, Zhang F. Lian XF, et al. World J Diabetes. 2022 Oct 15;13(10):877-887. doi: 10.4239/wjd.v13.i10.877. World J Diabetes. 2022. PMID: 36312002 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical